Status:
COMPLETED
To Evaluate the Influence of (LUA Probiotics) on Uric Acid
Lead Sponsor:
Grape King Bio Ltd.
Conditions:
Gout
Eligibility:
All Genders
20-90 years
Brief Summary
This study aims to investigate the efficacy of the lactic acid bacteria "LUA probiotics" in reducing serum uric acid levels. The use of health supplements prior to the onset of gout symptoms is propos...
Detailed Description
This study aims to investigate the efficacy of the lactic acid bacteria "LUA probiotics" in reducing serum uric acid levels. The use of health supplements prior to the onset of gout symptoms is propos...
Eligibility Criteria
Inclusion
- Collect 20 people, both male and female, aged 20 or above.
- Be conscious, willing to participate in the clinical observational research project, and complete the signed written consent form.
- Patients with hyperuricemia (uric acid level above 7.5 mg/dL) who have not taken uric acid-lowering drugs, and patients with gout who have not taken uric acid-lowering drugs, regardless of gender.
Exclusion
- Patients diagnosed by a physician as suffering from a major injury or illness listed by the National Health Insurance Administration.
- Pregnant women or women who plan to become pregnant within six months.
- Patients with abnormal liver function (AST, ALT greater than 2 times the upper limit of normal).
- Patients with abnormal renal function (serum creatinine \> 1.5 mg/dL).
- Patients with gastrointestinal dysfunction (surgery, frequent diarrhea).
- Those who must continue to take antibiotics, histamine-2 antagonists, proton pump inhibitors, antioxidants, probiotics, laxatives and other drugs.
- Patients with serious complications such as stroke, myocardial infarction, or major trauma or surgery in the past six months.
- People who are allergic to Lactobacillus.
- Subjects who are unable to exercise their right to consent on their own.
- Those who have irregular eating habits and are unable to cooperate with the plan implementation.
- Those who have poor compliance with doctor's orders.
Key Trial Info
Start Date :
July 18 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 8 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06969469
Start Date
July 18 2022
End Date
August 8 2024
Last Update
May 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100229